Related Experiment Video
Updated: Aug 24, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Construction of group sequential designs in clinical trials on the basis of detectable treatment differences
Helmut Schäfer1, Hans-Helge Müller
1Institute of Medical Biometry and Epidemiology, Philipps-University Marburg, Bunsenstrabetae 3, D-35037 Marburg, Germany. hsimbe@mailer.uni-marburg.de
Abstract:
The treatment effect sizes that can be detected with sufficient power up to the different interim analyses constitute a clinically meaningful criterion for the selection of a group sequential test for a clinical trial. For any pre-specified sequence of effect sizes, it is possible to construct group sequential boundaries such that the trial has a pre-specified power to reject the null-hypothesis at or before the corresponding interim analysis under the respective treatment effect. The principle of constructing group sequential designs on the basis of detectable treatment effects is presented. The application in common situations such as two-armed trials with continuous or binary outcome or censored survival times is described. We also present an effective algorithm.
Related Concept Videos
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Comparing the Survival Analysis of Two or More Groups
Clinical Trials: Overview
